Literature DB >> 31012246

Utilization of palliative care consultations in pediatric oncology phase I clinical trials.

Andrea Cuviello1,2, Renee Boss1, Nirali Shah2, Haven Battles2, Andrea Beri2, Lori Wiener2.   

Abstract

Pediatric phase I clinical oncology trials represent a unique cohort of patients who have not responded to standard therapies and remain highly vulnerable to treatment toxicity and/or disease burden. Incorporating a palliative care consultation into the care plan for those with relapsed/refractory cancer where chance of cure is limited is generally recommended. A retrospective chart review of pediatric phase I trials revealed that palliative care was consulted in <20% of patients, most often for symptom management. Efforts to increase the use of palliative services in this population may enhance quality of life for children and families enrolled in phase I studies.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  palliative care; pediatric oncology; phase I trial; quality of life; symptom management

Mesh:

Year:  2019        PMID: 31012246      PMCID: PMC7023673          DOI: 10.1002/pbc.27771

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  16 in total

1.  Chemotherapy versus supportive care alone in pediatric palliative care for cancer: comparing the preferences of parents and health care professionals.

Authors:  Deborah Tomlinson; Ute Bartels; Janet Gammon; Pamela S Hinds; Jocelyne Volpe; Eric Bouffet; Dean A Regier; Sylvain Baruchel; Mark Greenberg; Maru Barrera; Hilary Llewellyn-Thomas; Lillian Sung
Journal:  CMAJ       Date:  2011-10-17       Impact factor: 8.262

2.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Authors:  Daniel W Lee; James N Kochenderfer; Maryalice Stetler-Stevenson; Yongzhi K Cui; Cindy Delbrook; Steven A Feldman; Terry J Fry; Rimas Orentas; Marianna Sabatino; Nirali N Shah; Seth M Steinberg; Dave Stroncek; Nick Tschernia; Constance Yuan; Hua Zhang; Ling Zhang; Steven A Rosenberg; Alan S Wayne; Crystal L Mackall
Journal:  Lancet       Date:  2014-10-13       Impact factor: 79.321

3.  A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.

Authors:  S Weitman; A M Langevin; R L Berkow; P J Thomas; C A Hurwitz; A S Kraft; R L Dubowy; D L Smith; M Bernstein
Journal:  Clin Cancer Res       Date:  1999-09       Impact factor: 12.531

4.  Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report.

Authors:  Jack M Su; Xiao-Nan Li; Patrick Thompson; Ching-Nan Ou; Ashish M Ingle; Heidi Russell; Ching C Lau; Peter C Adamson; Susan M Blaney
Journal:  Clin Cancer Res       Date:  2010-11-29       Impact factor: 12.531

5.  Does phase 1 trial enrollment preclude quality end-of-life care? Phase 1 trial enrollment and end-of-life care characteristics in children with cancer.

Authors:  Deena R Levine; Liza-Marie Johnson; Belinda N Mandrell; Jie Yang; Nancy K West; Pamela S Hinds; Justin N Baker
Journal:  Cancer       Date:  2014-12-29       Impact factor: 6.860

6.  Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.

Authors:  Maryam Fouladi; Julie R Park; Clinton F Stewart; Richard J Gilbertson; Paula Schaiquevich; Junfeng Sun; Joel M Reid; Matthew M Ames; Roseanne Speights; Ashish M Ingle; James Zwiebel; Susan M Blaney; Peter C Adamson
Journal:  J Clin Oncol       Date:  2010-07-06       Impact factor: 44.544

7.  A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.

Authors:  Terzah M Horton; Debananda Pati; Sharon E Plon; Patrick A Thompson; Lisa R Bomgaars; Peter C Adamson; Ashish M Ingle; John Wright; Adam H Brockman; Martin Paton; Susan M Blaney
Journal:  Clin Cancer Res       Date:  2007-03-01       Impact factor: 12.531

8.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

9.  Characteristics and outcome of pediatric patients enrolled in phase I oncology trials.

Authors:  Aerang Kim; Elizabeth Fox; Katherine Warren; Susan M Blaney; Stacey L Berg; Peter C Adamson; Madeleine Libucha; Elena Byrley; Frank M Balis; Brigitte C Widemann
Journal:  Oncologist       Date:  2008-06

10.  The impact of palliative care consultation on symptom assessment, communication needs, and palliative interventions in pediatric patients with cancer.

Authors:  Donna S Zhukovsky; Cynthia E Herzog; Guddi Kaur; J Lynn Palmer; Eduardo Bruera
Journal:  J Palliat Med       Date:  2009-04       Impact factor: 2.947

View more
  2 in total

1.  Specialist paediatric palliative care for children and young people with cancer: A mixed-methods systematic review.

Authors:  Johanna Taylor; Alison Booth; Bryony Beresford; Bob Phillips; Kath Wright; Lorna Fraser
Journal:  Palliat Med       Date:  2020-05-02       Impact factor: 4.762

2.  Oncologist conceptualizations of pediatric palliative care: challenges and definitions.

Authors:  Anat Laronne; Leeat Granek; Lori Wiener; Paula Feder-Bubis; Hana Golan
Journal:  Support Care Cancer       Date:  2021-01-03       Impact factor: 3.359

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.